Industry Outlook

Bronchitis treatment market accounted for a market value of US$ 3,509.7 Mn in 2021 and is projected to grow at a CAGR of 4.9% during the forecast period from 2023 to 2030. Bronchitis treatment market is growing gradually throughout the forecast period due to strong product pipeline equipped with target-specific drugs, and rising prevalence & awareness related to the treatment & diagnosis of bronchitis. The major cause of bronchitis is frequent cigarette smoking coupled with exposure to air-pollutants.  Thus, overall growth of global bronchitis treatment is significant and expected to maintain its growth throughout the forecast year with the help of upcoming drugs currently present under trials.

"Continuous research & development in the field of bronchitis treatment expected to bring novel drugs in the market & ultimately assist the overall growth"

During the forecast period from 2023 to 2030, phospodiesterase-4inhibitors identified as the fastest growing segment due to major factors such as Roflumilast are beneficial in chronic bronchitis to decrease exacerbations & relieve dyspnea, and physicians treat chronic bronchitis on priority as its more complex compared to acute bronchitis. Roflumilast also plays key role in improving the lung function and assists recovery of patients. Thus, novel drugs entering in the market will increase the growth of overall bronchitis treatment market, as there is huge market demand for target-specific drugs in the market.

"Increasing prevalence & awareness related to the bronchitis in Asia Pacific makes it the fastest growing region throughout the forecast period"

The Asia Pacific will grow significantly throughout the forecast period from 2023 to 2030, the key factors responsible for growth of bronchitis treatment market in this region are rising prevalence of bronchitis due to high level of air-pollution & smoking population, and increasing awareness and accessibility related to bronchitis treatment. There are several awareness campaigns carried out by government and non-government organizations in developing countries of Asia Pacific such as China, India, Indonesia, and Thailand due to which bronchitis treatment market is growing significantly in this region. China & India have highest population suffering with bronchitis that mainly caused due to air-pollution and huge cigarette smoking population. According to World Health Organization (WHO), it has been recorded that in Asia around one third or 2.2 million of the world’s 7 million premature deaths occur due to respiratory disorders caused due to air-pollution each year.

The key manufacturers present in the market reported based on product portfolio, current market updates, financial information, and key strategies. This report also include attractive investment proposition studied with the aid of PESTEL analysis, which based on detailed geographical research. Major companies studied in the overall report are AstraZeneca Plc, DBV Technologies SA, F. Hoffmann-La Roche Ltd., Han Wha Pharma Co. Ltd., and Mucosis BV among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Bronchitis Treatment market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Bronchitis Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Bronchitis Treatment market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Bronchitis Treatment market?
• Which is the largest regional market for Bronchitis Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Bronchitis Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Bronchitis Treatment market worldwide?